Drugs / VRX496-Modified Autologous T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00131560 | Jul 2005 → Nov 2008 | HIV infectious disease | VIRxSYS Corporation | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRX496-Modified Autologous T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00131560 ↗ |
| Modality | Cell therapy | “autologous (one's own) CD4 T cells modified with a viral vector expressing a genetic antisense targeting HIV” NCT00131560 ↗ |
| Route | Intravenous | “Study treatment is by intravenous infusion of vector modified cells” NCT00131560 ↗ |